Literature DB >> 28203772

Elevated Pre-Antiretroviral Therapy CD39+CD8+ T Cell Frequency Is Associated With Early Mortality in Advanced Human Immunodeficiency Virus/Tuberculosis Co-infection.

Shruthi Ravimohan1,2, Neo Tamuhla2, Kebatshabile Nfanyana2, Houping Ni1, Andrew P Steenhoff3,2,4, Robert Gross1,2,5, Drew Weissman1,2, Gregory P Bisson1,2,5.   

Abstract

Correlates of death soon after antiretroviral therapy (ART) initiation remain unclear. We investigated the association between expression of CD39, a novel immune exhaustion marker, and early mortality in patients with human immunodeficiency virus/tuberculosis co-infection. Elevated pre-ART CD39+CD8+ T cell frequency was independently associated with mortality within 6 months of ART initiation.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CD39; CD8+ T cells.; HIV; early mortality; tuberculosis

Mesh：

Substances：

Year:  2017        PMID： 28203772      PMCID： PMC5411394          DOI： 10.1093/cid/cix155

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  16 in total

1.  Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells.

Authors:  Deborah A Lewinsohn; Amy S Heinzel; James M Gardner; Liqing Zhu; Mark R Alderson; David M Lewinsohn
Journal:  Am J Respir Crit Care Med       Date:  2003-09-11       Impact factor: 21.405

2.  CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.

Authors:  Gregory M Hayes; Belinda Cairns; Zoia Levashova; Lawrence Chinn; Myra Perez; Jan-Willem Theunissen; Sindy Liao-Chan; Abel Bermudez; Mark R Flory; Karl J Schweighofer; Edward H van der Horst
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

3.  HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Authors:  Simone C Zimmerli; Alexandre Harari; Cristina Cellerai; Florence Vallelian; Pierre-Alexandre Bart; Giuseppe Pantaleo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-04       Impact factor: 11.205

4.  Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

Review 5.  ENTPD1/CD39 is a promising therapeutic target in oncology.

Authors:  J Bastid; A Cottalorda-Regairaz; G Alberici; N Bonnefoy; J-F Eliaou; A Bensussan
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

6.  CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.

Authors:  Mardi C Boer; Krista E van Meijgaarden; Jérémy Bastid; Tom H M Ottenhoff; Simone A Joosten
Journal:  Eur J Immunol       Date:  2013-05-29       Impact factor: 5.532

7.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.

Authors:  Michael R Betts; Martha C Nason; Sadie M West; Stephen C De Rosa; Stephen A Migueles; Jonathan Abraham; Michael M Lederman; Jose M Benito; Paul A Goepfert; Mark Connors; Mario Roederer; Richard A Koup
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

8.  CD39/adenosine pathway is involved in AIDS progression.

Authors:  Maria Nikolova; Matthieu Carriere; Mohammad-Ali Jenabian; Sophie Limou; Mehwish Younas; Ayrin Kök; Sophie Huë; Nabila Seddiki; Anne Hulin; Olivier Delaneau; Hanneke Schuitemaker; Joshua T Herbeck; James I Mullins; Maria Muhtarova; Armand Bensussan; Jean-François Zagury; Jean-Daniel Lelievre; Yves Lévy
Journal:  PLoS Pathog       Date:  2011-07-07       Impact factor: 6.823

9.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells.

Authors:  Prakash K Gupta; Jernej Godec; David Wolski; Emily Adland; Kathleen Yates; Kristen E Pauken; Cormac Cosgrove; Carola Ledderose; Wolfgang G Junger; Simon C Robson; E John Wherry; Galit Alter; Philip J R Goulder; Paul Klenerman; Arlene H Sharpe; Georg M Lauer; W Nicholas Haining
Journal:  PLoS Pathog       Date:  2015-10-20       Impact factor: 6.823

Review 10.  Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis.

Authors:  Rishi K Gupta; Sebastian B Lucas; Katherine L Fielding; Stephen D Lawn
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177
View more
  3 in total

1.  Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study.

Authors:  Linda Boloko; Charlotte Schutz; Nomfundo Sibiya; Avuyonke Balfour; Amy Ward; Muki Shey; Mark P Nicol; Rosie Burton; Robert J Wilkinson; Gary Maartens; Graeme Meintjes; David A Barr
Journal:  Lancet Microbe       Date:  2022-05-26

2.  CD39 as a marker of pathogenic CD8+ T cells in cancer and other chronic inflammatory diseases.

Authors:  Fernando Pablo Canale; María Cecilia Ramello; Carolina Lucía Montes
Journal:  Oncoscience       Date:  2018-04-29

3.  Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways.

Authors:  Jing Li; Hui-Huang Huang; Bo Tu; Ming-Ju Zhou; Wei Hu; Yu-Long Fu; Xiao-Yu Li; Tao Yang; Jin-Wen Song; Xing Fan; Yan-Mei Jiao; Ruo-Nan Xu; Ji-Yuan Zhang; Chun-Bao Zhou; Jin-Hong Yuan; Cheng Zhen; Ming Shi; Fu-Sheng Wang; Chao Zhang
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.